Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase III multicentre randomised clinical trial comparing rituximab with CHOP [cyclophosphamide, doxorubicin, vincristine, prednisone] given every 14 days and rituximab with CHOP given every 21 days for the treatment of patients with newly diagnosed diffuse large B cell non-Hodgkin's lymphoma.

X
Trial Profile

A phase III multicentre randomised clinical trial comparing rituximab with CHOP [cyclophosphamide, doxorubicin, vincristine, prednisone] given every 14 days and rituximab with CHOP given every 21 days for the treatment of patients with newly diagnosed diffuse large B cell non-Hodgkin's lymphoma.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 06 Apr 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Rituximab (Primary) ; Cyclophosphamide; Doxorubicin; Prednisone; Vincristine
  • Indications Diffuse large B cell lymphoma
  • Focus Pharmacogenomic; Registrational; Therapeutic Use
  • Acronyms R-CHOP 14 vs 21
  • Most Recent Events

    • 13 Mar 2020 Results comparing International prognostic indices in diffuse large B-cell lymphoma using different trials published in the Blood
    • 01 Oct 2017 Results of a analysis assessing CNS relapse fro patients published in the Annals of Oncology
    • 28 May 2013 Status changed from active, no longer recruiting to completed as reported by ISRCTN: Current Controlled Trials.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top